Targeting von Willebrand factor as a novel anti-platelet therapy; Application of ARC1779, an Anti-vWF aptamer, against thrombotic risk

Excessive activation of platelets is a causative factor for thrombotic diseases such as acute coronary syndrome or stroke, and various anti-platelet drugs were developed. Aspirin and clopidogrel have been used as gold standards for anti-platelet therapies, however, their clinical limitations includi...

Full description

Saved in:
Bibliographic Details
Published in:Archives of pharmacal research 2012, 35(10), , pp.1693-1699
Main Author: Bae, Ok-Nam
Format: Article
Language:English
Subjects:
Animals
Aptamers, Nucleotide - administration & dosage
Aptamers, Nucleotide - chemistry
Aptamers, Nucleotide - pharmacology
Aptamers, Nucleotide - therapeutic use
Clinical Trials as Topic
Drug Evaluation, Preclinical
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Humans
Medicine
Pharmacology/Toxicology
Pharmacy
Platelet Activation - drug effects
Platelet Aggregation - drug effects
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - chemistry
Platelet Aggregation Inhibitors - pharmacology
Platelet Aggregation Inhibitors - therapeutic use
Report on Investigational Drugs
Thrombosis - blood
Thrombosis - prevention & control
Treatment Outcome
von Willebrand Factor - antagonists & inhibitors
von Willebrand Factor - chemistry
약학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Excessive activation of platelets is a causative factor for thrombotic diseases such as acute coronary syndrome or stroke, and various anti-platelet drugs were developed. Aspirin and clopidogrel have been used as gold standards for anti-platelet therapies, however, their clinical limitations including bleeding problem have increased the demand driving development of novel anti-platelet drugs with new targets. Among several activating pathways leading to platelet aggregation, the interaction between von Willebrand factor (vWF) and glycoprotein Ib, which mainly occurs under high shear stress in arterioles, is recently suggested to be a new promising target. The anti-thrombotic efficacy of anti-vWF agents, such as ARC1779, has been proved in several preclinical and clinical studies. Here, we will discuss the potential benefits of targeting vWF as a novel antiplatelet therapy, providing an insight into the role of vWF in increased thrombotic risk.
ISSN:0253-6269
1976-3786
DOI:10.1007/s12272-012-1000-3